OLD GREENWICH, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) ("Star" or the "Company"), a diversified holding company, announced today that its management team will present and host one-on-one meetings with investors at Noble Capital Markets Emerging Growth Virtual Conference, which will take place from June 3-4, 2026.
WEST PALM BEACH, Fla., June 2, 2026 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together hold an investment of well...
WEST PALM BEACH, Fla., June 1, 2026 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together hold an investment of well...
WEST PALM BEACH, Fla., June 1, 2026 /CNW/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together hold an investment of well...
WEST PALM BEACH, Fla., June 1, 2026 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together hold an investment of well...
WEST PALM BEACH, Fla., June 1, 2026 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together hold an investment of well...
On 1 June 2026, Giedrė Kaminskaitė-Salters, CEO of Telia Lietuva, made a presentation to investors at Nasdaq Baltic organized event CEO Meets Investors.
BEVERLY, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ATNI), a leading provider of digital infrastructure and communications services, today announced that management will participate in the 16th Annual East Coast IDEAS Investor Conference at The Westin New York at Times Square on June 11, 2026.
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.
Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.